Bellicum announces trial holds for switch T cell candidates

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said FDA placed a clinical hold on U.S. trials of the company's adjunct, safety switch-containing T cell therapy BPX-501 in patients receiving partial match hematopoietic stem cell transplants (HSCTs). According to the

Read the full 368 word article

User Sign In